Sven-Ã…ke Henningsson, member of CellaVision Board since 2006 and Chairman of the Audit Committee, has been appointed Acting CFO from September 1 until a permanent successor has been appointed. Â
CellaVision's Chief Financial Officer since 2007, Johan Wennerholm, will resign at the end of September for new challenges outside the group. The process of recruiting a new CFO has begun.
"I am very pleased and grateful that Sven-Åke has agreed to take the position as Acting CFO. Sven-Åke has very good insight into CellaVision and with his deep experience and expertise this is a perfect solution until we found a successor to John Wennerholm", says Yvonne Mårtensson, CEO of CellaVision. "Johan has done a fantastic job during his years at CellaVision, including being a driving force in the process of listing CellaVision on Nasdaq OMX Small Cap in 2010. He has been very important for the company's development and has contributed to improvements in areas throughout our organization. I wish him all the best in his new challenges."
Sven-Åke Henningsson is former CEO of Kanthal-Höganäs, AB Wilh Becker and Lindéngruppen AB, and has held the position as CFO in several companies. He serves on the board for Rittal Scandinavian AB and Gant Company AB among others. Sven-Åke Henningsson will temporarily be replaced by board member Anna Malm Bernsten in CellaVision's Audit Committee. Lars Henriksson, member of the board, takes a temporary position as chairman of the committee.
For further information, please contact:
Yvonne MÃ¥rtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82. Email: yvonne.martensson@cellavision.com (mailto:yvonne.martensson@cellavision.com)Â
Â
Â
About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The analyses often constitute important reference data for fast and correct diagnosis of illnesses, for example of infections and serious cancers. CellaVision's products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In 2011 sales were SEK 155 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund and the company has subsidiaries in the USA, Canada and Japan. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com (http://www.cellavision.com). Â
CellaVision's Chief Financial Officer since 2007, Johan Wennerholm, will resign at the end of September for new challenges outside the group. The process of recruiting a new CFO has begun.
"I am very pleased and grateful that Sven-Åke has agreed to take the position as Acting CFO. Sven-Åke has very good insight into CellaVision and with his deep experience and expertise this is a perfect solution until we found a successor to John Wennerholm", says Yvonne Mårtensson, CEO of CellaVision. "Johan has done a fantastic job during his years at CellaVision, including being a driving force in the process of listing CellaVision on Nasdaq OMX Small Cap in 2010. He has been very important for the company's development and has contributed to improvements in areas throughout our organization. I wish him all the best in his new challenges."
Sven-Åke Henningsson is former CEO of Kanthal-Höganäs, AB Wilh Becker and Lindéngruppen AB, and has held the position as CFO in several companies. He serves on the board for Rittal Scandinavian AB and Gant Company AB among others. Sven-Åke Henningsson will temporarily be replaced by board member Anna Malm Bernsten in CellaVision's Audit Committee. Lars Henriksson, member of the board, takes a temporary position as chairman of the committee.
For further information, please contact:
Yvonne MÃ¥rtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82. Email: yvonne.martensson@cellavision.com (mailto:yvonne.martensson@cellavision.com)Â
Â
Â
About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The analyses often constitute important reference data for fast and correct diagnosis of illnesses, for example of infections and serious cancers. CellaVision's products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In 2011 sales were SEK 155 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund and the company has subsidiaries in the USA, Canada and Japan. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com (http://www.cellavision.com). Â
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
HUG#1623886
© 2012 GlobeNewswire (Europe)
